Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes
STRIDE has enrolled participants with symptomatic PAD and T2D, frequent risk factors and comorbidities, and functional impairment. The trial will provide evidence for the functional outcomes with semaglutide in people with PAD and T2D.
Authors
- Andrei‐Mircea Catarig (ORCID: https://orcid.org/0000-0002-7667-8315)
- Bernhard Ludvik (ORCID: https://orcid.org/0009-0003-8717-8396)
- Yasemin Hansen
- Joakim Nordanstig (ORCID: https://orcid.org/0000-0002-2670-2268)
- Harald Sourij (ORCID: https://orcid.org/0000-0003-3510-9594)
- Kim Christian Houlind (ORCID: https://orcid.org/0000-0002-1600-4415)
- Subodh Verma (ORCID: https://orcid.org/0000-0002-4018-8533)
- Neda Rasouli (ORCID: https://orcid.org/0000-0003-1269-3580)
- Marc P. Bonaca (ORCID: https://orcid.org/0000-0002-9860-3584)
- Chethana Ramesh
Institutions
- St. Michael's Hospital (CA)
- University of Southern Denmark (DK)
- University of Toronto (CA)
- Novo Nordisk (Denmark) (DK)
- Medical University of Graz (AT)
- Lillebaelt Hospital (DK)
- Novo Nordisk (India) (IN)
- Karl Landsteiner Society (AT)
- University of Gothenburg (SE)
- University of Colorado Denver (US)
Publication Details
- Journal
- European Heart Journal - Cardiovascular Pharmacotherapy
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1093/ehjcvp/pvae071
- Citations
- 19
- Primary Topic
- Peripheral Artery Disease Management
- Type
- article
- Field-Weighted Citation Impact
- 10.88
Funders
- Novo Nordisk